Amgen PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
By Patrick Wingrove (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie (NYSE:ABBV) Inc’s blockbuster arthritis drug Humira this year, but the cost...
By Sriparna Roy and Michael Erman (Reuters) -Amgen Inc on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower...
The disinflation process has started. US oil inventory builds collide with cheap Russian oil Hope for a Fed pause is driving sentiment. Markets US equities were stronger...
The US economy should witness a further slowdown in 2023 With inflation still running hot and the Fed raising rates to battle it, investors need to be prudent with their investment...
Looking for the Dogs of the Dow, 2023 edition? You came to the right place. We’ll explore these 10 blue-chip dividend bargains in a moment. Collectively, they are yielding...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
| Average | 268.600 (+8.952% Upside) |
| High | 325.000 |
| Low | 180.000 |
| Price | 246.530 |
| No. of Analysts | 21 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Sell | Sell | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 188.27 | 196.75 | 182.61 | +6.86 | +3.78% | 214.41M | NASDAQ | |||
| 49.32 | 49.56 | 48.35 | +0.75 | +1.54% | 17.83M | NASDAQ | |||
| 96.65 | 97.50 | 95.84 | +1.91 | +2.02% | 14.79M | NYSE | |||
| 188.77 | 197.16 | 180.16 | +35.65 | +23.28% | 149.57M | NASDAQ | |||
| 120.29 | 120.85 | 115.51 | +4.43 | +3.82% | 4.91M | NYSE | |||
| 751.20 | 758.72 | 741.45 | -6.80 | -0.90% | 921.75K | NASDAQ | |||
| 379.34 | 380.24 | 360.29 | +26.57 | +7.53% | 617.50K | NYSE | |||
| 263.21 | 265.98 | 262.02 | -3.06 | -1.15% | 3.72M | NYSE | |||
| 60.28 | 61.02 | 59.91 | -1.05 | -1.71% | 16.77M | NYSE | |||
| 38.32 | 38.63 | 38.08 | -0.41 | -1.06% | 2.76M | NYSE | |||
| 214.50 | 217.38 | 209.28 | +12.39 | +6.13% | 3.79M | NYSE | |||
| 108.80 | 108.82 | 106.54 | +7.37 | +7.27% | 43.60M | NASDAQ | |||
| 38.04 | 38.55 | 37.57 | +0.61 | +1.63% | 940.36K | NYSE | |||
| 17.89 | 18.88 | 17.45 | +0.21 | +1.19% | 25.47M | NASDAQ | |||
| 3.82 | 4.06 | 3.72 | -0.03 | -0.78% | 261.26K | NASDAQ |